MedPath

Sincalide

Generic Name
Sincalide
Brand Names
Kinevac
Drug Type
Biotech
CAS Number
25126-32-3
Unique Ingredient Identifier
M03GIQ7Z6P

Overview

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion in the body. When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. As the product Kinevac (FDA), sincalide is used to stimulate the duodenum, pancreas, and small bowel for cholesterol analysis, enzymatic activity analysis, and x-ray examination respectively.

Background

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion in the body. When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. As the product Kinevac (FDA), sincalide is used to stimulate the duodenum, pancreas, and small bowel for cholesterol analysis, enzymatic activity analysis, and x-ray examination respectively.

Indication

As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.

Associated Conditions

No associated conditions information available.

FDA Approved Products

KINEVAC
Manufacturer:Bracco Diagnostics Inc.
Route:INTRAVENOUS
Strength:5 ug in 5 mL
Approved: 2018/01/22
NDC:0270-0556
Sincalide
Manufacturer:MAIA Pharmaceuticals, Inc.
Route:INTRAVENOUS
Strength:5 ug in 5 mL
Approved: 2023/11/01
NDC:70511-131
SINCALIDE
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:5 ug in 5 mL
Approved: 2018/01/22
NDC:63323-579
Sincalide
Manufacturer:FOSUN PHARMA USA INC
Route:INTRAVENOUS
Strength:5 ug in 5 mL
Approved: 2022/12/13
NDC:72266-248
SIncalide
Manufacturer:AnazaoHealth Corporation
Route:INTRAVENOUS
Strength:3 ug in 1 1
Approved: 2012/06/30
NDC:51808-203

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath